Zydus Lifesciences Limited
https://www.zyduslife.com/index
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Zydus Lifesciences Limited
Zydus Signs MRI Contrast Agent Licensing Deal With A Market Worth Of $237m
Zydus bags two generic gadolinium-based contrasting agents in an exclusive licensing and supply agreement with Viwit, opening a new chapter of imaging injectables for the US market.
US Generics Players Enjoy Calmer Waters
After years of heavy price and cost pressures that have taken a toll on firms operating in the US generics market, more recent quarters appear to have reflected a calmer and more predictable landscape.
Generics Bulletin Explains: US Generics Players Enjoy Calmer Waters
After years of heavy price and cost pressures that have taken a toll on firms operating in the US generics market, more recent quarters appear to have reflected a calmer and more predictable landscape. Generics Bulletin looks at the latest trends.
FDA Rebukes Zydus Injectables Facility For Glass Contamination, Aseptic Oversight
Zydus Lifesciences must provide the US Food and Drug Administration with a detailed action plan addressing specific violations of current good manufacturing practice at its injectables site in Vadodara, Gujarat.
Company Information
- Industry
-
Pharmaceuticals
- Generic Drugs
- OTC, Consumer
- Other Names / Subsidiaries
-
- Cadila Healthcare
- Zydus Pharmaceuticals USA
- German Remedies
- Zynesher Pharmaceuticals USA LLC
- Nesher Pharmaceuticals Inc
- Quimica e Farmaceutica Nikkho do Brasil Ltda
- Bremer Pharma GmbH
- Nippon Universal Pharmaceuticals
- Zydus Discovery DMCC
- Zydus Urosciences
- Sentynl Therapeutics, Inc
- Zydus Lifesciences Ltd
- Cadila Healthcare Ltd.
- Zydus Cadila
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice